Skip to Content

Safeguard Your Intellectual Property ®

SSJR Client Apotex Obtains Order Increasing Total Bond Amount to $442 Million After Successful Budesonide Trial

SSJR has successfully moved the Court of Appeals for the Federal Circuit to require an additional $130 million bond from AstraZeneca, adding to existing bonds of $312 million, to allow recovery of damages and costs sustained by SSJR’s client Apotex as a result of an injunction. If the trial court’s […]

Read More

March 12, 2015 by in General

SSJR Wins Patent Infringement Trial for Apotex Regarding Budesonide (Pulmicort Respules®)

On February 13, 2015, SSJR, for its client Apotex, won a patent trial against AstraZeneca, lifting an injunction and clearing the path for Apotex to enter the $1.1 billion annual Pulmicort Respules® market with a generic version of the popular asthma drug. SSJR will now be seeking damages as compensation […]

Read More

February 23, 2015 by in General